The use of specific small molecule inhibitors of mutant BRAF in patients with tumors harboring a BRAF V600 mutation has demonstrated that neither within, nor across, cancer frequency is sufficient to determine the functional significance of inhibiting “driver” mutations [5]. Here, BRAF is linked to cancer.